mutations and complicated kar yotype. It follows a linear evolution from the CLL clone in the recurrent acquisition of CDKN2A Not all patients with CLL need therapy. Regardless of all current advances, the iwCLL nonetheless recommends watchful observation for sufferers with asymptomatic disorder.